Safety of resuming tumor necrosis factor inhibitors in ankylosing spondylitis patients concomitant with the treatment of active tuberculosis: A retrospective nationwide registry of the Korean Society of spondyloarthritis research

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Kim, Hye Won ^a   Kwon, Seong Ryul ^b   Jung, Kyong Hee ^b   Kim, Seong Kyu ^c   Baek, Han Joo ^d   Seo, Mi Ryung ^d   Bang, So Young ^e   Lee, Hye Soon ^e   Suh, Chang Hee ^f   Jung, Ju Yang ^f   Son, Chang Nam ^g   Shim, Seung Cheol ^h   Lee, Sang Hoon ⁱ   Lee, Seung Geun ^j   Lee, Yeon Ah ⁱ   Lee, Eun Young ^k   Kim, Tae Hwan ^l   Kim, Yong Gil ^m   Kang, Kwi Young ⁿ   Kang, Mi Il ^o   Koo, Bon San ^p   Kim, Dam ^l   Kim, You Jae ^m   Kim, Joong Gon ^q   Kim, Jin Ju ^q   Kim, Tae Jong ^r   Kim, Hyung Jin ^s   Ryu, Hee Jung ^d   Yoo, Hyun Jeong ^t   Park, Ye Soo ^e   Park, Min Chan ^a   Bae, Chang Bum ^d   Seo, Young Ho ^u   Sung, Duk Hyun ^s   Sung, Yoon Kyoung ^q   Song, Ran ⁱ   Shin, Kichul ^q   Sheen, Dong Hyuk ^v   Oh, Ji Min ^w   Yoo, Tae Seok ^x   Lee, Sang Yeob ^y   Lee, Sang Heon ^z   Lee, Seunghun ^aa   Lee, Jaejoon ^v   Lee, Jae Myung ^ab   Lim, Mi Kyoung ^v   Chang, Sung Hae ^ac   Jeong, Hyemin ^v   Cho, Soo Kyung ^q   Cho, Hyun Jung ^ad   Cho, Mi La ^ae   Joo, Young Bin ^q   Cha, Hoon Suk ^v   Choi, Seong Jae ^u   Choi, Ji Young ⁱ   Choi, Chan Bum ^l   Choi, Hyo Jin ^d   Hong, Seung Jae ⁱ   Hwang, Ji Won ^af   Hong, Seok Chan ^m   more..

^a Yonsei University College of Medicine   (South Korea)

^b Inha University School of Medicine   (South Korea)

^c Catholic University of Daegu   (South Korea)

^d Gachon University   (South Korea)

^e Hanyang University Guri Hospital   (South Korea)

^f Ajou University Medical CentSuwon   (South Korea)

^g Dongsan Medical Center   (South Korea)

^h Chungnam National University College of Medicine   (South Korea)

ⁱ Kyung Hee University College of Medicine   (South Korea)

^j Pusan National University School of Medicine   (South Korea)

^k Seoul National University Hospital   (South Korea)

^l Hanyang University Hospital for Rheumatic Diseases   (South Korea)

^m University of Ulsan College of Medicine   (South Korea)

ⁿ The Catholic University of Korea   (South Korea)

^o Dankook University   (South Korea)

^p Konkuk University School of Medicine   (South Korea)

^q Seoul National University College of Medicine   (South Korea)

^r Chonnam National University Medical School   (South Korea)

^s Sungkyunkwan University School of Medicine   (South Korea)

^t PFIZER INC   (United States)

^u Korea University College of Medicine   (South Korea)

^v Eulji University School of Medicine   (South Korea)

^w Anyang SAM Hospital   (South Korea)

^x YTS Rheumatology Clinic   (South Korea)

^y Dong A University College of Medicine   (South Korea)

^z Konkuk University Hospital   (South Korea)

^aa Hanyang University College of Medicine   (South Korea)

^ab Gangbyeon Rheuma Clinic   (South Korea)

^ac Soonchunhyang University   (South Korea)

^ad Seoul Dist Armed Forces Gen Hosp   (South Korea)

^ae The Catholic University of Korea   (South Korea)

^af National Police Hospital   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; ETHAMBUTOL; GOLIMUMAB; INFLIXIMAB; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; HUMAN; LATENT TUBERCULOSIS; LONG TERM EXPOSURE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; MIDDLE AGED; SOUTH KOREA; SPONDYLITIS, ANKYLOSING; TUBERCULOSIS;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84964819330     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153816     Document Type: Article

References (31)

1. Ergun T, Seckin D, Baskan Bulbul E, Onsun N, Ozgen Z, Unalan P, et al. The risk of tuberculosis in patients with psoriasis treated with anti-tumor necrosis factor agents. Int J Dermatol. 2015; 54(5):594-9. doi: 10.1111/ijd.12628 PMID: 25753908.
2. Baronnet L, Barnetche T, Kahn V, Lacoin C, Richez C, Schaeverbeke T. Incidence of tuberculosis in patients with rheumatoid arthritis. A systematic literature review. Joint Bone Spine. 2011; 78(3):279-84. doi: 10.1016/j.jbspin.2010.12.004 PMID: 21273108.
3. Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-alpha inhibitors: systematic review of the literature. Clin Infect Dis. 2013; 57(9):1318-30. doi: 10.1093/cid/cit489 PMID: 23899685; PubMed Central PMCID: PMC3888230.
4. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011; 306(21):2331-9. doi: 10.1001/jama.2011.1692 PMID: 22056398; PubMed Central PMCID: PMC3428224.
5. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax. 2005; 60(10):800-5. Epub 2005/08/02. doi: 10.1136/thx.2005.046797 PMID: 16055611; PubMed Central PMCID: PMCPMC1747200.
6. Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis. 2008; 8(10):601-11. PMID: 18922482. doi: 10.1016/S1473-3099(08)70227-5
7. Tam LS, Leung CC, Ying SK, Lee GK, Yim CW, Leung YY, et al. Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong-the role of TNF blockers in an area of high tuberculosis burden. Clin Exp Rheumatol. 2010; 28(5):679-85. PMID: 20822708.
8. Kim HW, Park JK, Yang JA, Yoon YI, Lee EY, Song YW, et al. Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area. Clin Rheumatol. 2014; 33(9):1307-12. doi: 10.1007/s10067-013-2387-z PMID: 24057090.
9. Jung SM, Ju JH, Park MS, Kwok SK, Park KS, Kim HY, et al. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden. Int J Rheum Dis. 2015; 18(3):323-30. Epub 2015/01/06. doi: 10.1111/1756-185x.12530 PMID: 25557144.
10. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010; 36(5):1185-206. doi: 10.1183/09031936.00028510 PMID: 20530046.
11. Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis. 2003; 62(8):791. PMID: 12860745; PubMed Central PMCID: PMC1754631.
12. Braun J, Kiltz U, Heldmann F, Baraliakos X. Emerging drugs for the treatment of axial and peripheral spondyloarthritis. Expert Opin Emerg Drugs. 2015; 20(1):1-14. doi: 10.1517/14728214.2015.993378 PMID: 25575936.
13. Baraliakos X, van den Berg R, Braun J, van der Heijde D. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology (Oxford). 2012; 51(8):1378-87. doi: 10.1093/rheumatology/ kes026 PMID: 22427410.
14. Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015; 4:CD005468. doi: 10.1002/ 14651858.CD005468.pub2 PMID: 25887212.
15. Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther. 2005; 7(3):R439-44. doi: 10.1186/ar1693 PMID: 15899030; PubMed Central PMCID: PMC1174938.
16. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000; 43(6):1346-52. doi: 10.1002/1529-0131(200006)43:6〈1346::AID-ANR18〉3.0.CO;2-E PMID: 10857793.
17. Cantini F, Prignano F, Goletti D. Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment. J Rheumatol Suppl. 2014; 91:78-82. doi: 10.3899/jrheum.140106 PMID: 24789004.
18. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27(4):361-8. PMID: 6231933.
19. Joint Committee for the Revision of Korean Guidelines for Tuberculosis KCfDCaP. Joint Committee for the Revision of Korean Guidelines for Tuberculosis, Korean Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. 2nd ed. Seoul and Cheongwon. 2014.
20. Kim YJ, Kim YG, Shim TS, Koo BS, Hong S, Lee CK, et al. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors. Rheumatology (Oxford). 2014; 53(8):1477-81. doi: 10.1093/rheumatology/keu041 PMID: 24681840.
21. Suh YS, Kwok SK, Ju JH, Park KS, Park SH, Yoon CH. Safe re-administration of tumor necrosis factoralpha (TNFalpha) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFalpha therapy. J Korean Med Sci. 2014; 29(1):38-42. doi: 10.3346/jkms.2014.29.1.38 PMID: 24431903; PubMed Central PMCID: PMC3890474.
22. Denis B, Lefort A, Flipo RM, Tubach F, Lemann M, Ravaud P, et al. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment. Clin Microbiol Infect. 2008; 14 (2):183-6. doi: 10.1111/j.1469-0691.2007.01891.x PMID: 18076664.
23. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345 (15):1098-104. doi: 10.1056/NEJMoa011110 PMID: 11596589.
24. Abreu C, Magro F, Santos-Antunes J, Pilao A, Rodrigues-Pinto E, Bernardes J, et al. Tuberculosis in anti-TNF-alpha treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population. J Crohns Colitis. 2013; 7(10):e486-92. doi: 10.1016/j. crohns.2013.03.004 PMID: 23583099.
25. Karakousis PC, Yoshimatsu T, Lamichhane G, Woolwine SC, Nuermberger EL, Grosset J, et al. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med. 2004; 200(5):647-57. doi: 10.1084/jem.20040646 PMID: 15353557; PubMed Central PMCID: PMC2212740.
26. Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis. 2009; 48(10):1429-32. doi: 10.1086/598504 PMID: 19364287.
27. Poddubnyy D. Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet Dis. 2013; 5(1):45-54. Epub 2013/03/22. PMID: 23514983; PubMed Central PMCID: PMCPmc3582305. doi: 10.1177/1759720X12468658
28. Gomez-Reino JJ, Carmona L, Angel Descalzo M, Biobadaser G. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007; 57(5):756-61. doi: 10.1002/art.22768 PMID: 17530674.
29. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005; 52(6):1766-72. doi: 10.1002/art. 21043 PMID: 15934089.
30. Lee YM, Lee SO, Choi SH, Kim YS, Woo JH, Kim DY, et al. A prospective longitudinal study evaluating the usefulness of the interferon-gamma releasing assay for predicting active tuberculosis in allogeneic hematopoietic stem cell transplant recipients. J Infect. 2014; 69(2):165-73. Epub 2014/03/22. PMID: 24647146. doi: 10.1016/j.jinf.2014.02.019
31. Evangelopoulos D, da Fonseca JD, Waddell SJ. Understanding anti-tuberculosis drug efficacy: rethinking bacterial populations and how we model them. Int J Infect Dis. 2015; 32:76-80. doi: 10.1016/j.ijid. 2014.11.028 PMID: 25809760.